Indivior PLC (NASDAQ:INDV) Stake Trimmed by Madison Avenue Partners LP

Madison Avenue Partners LP lowered its stake in shares of Indivior PLC (NASDAQ:INDV - Free Report) by 7.3% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 3,673,426 shares of the company's stock after selling 287,346 shares during the quarter. Indivior makes up about 4.8% of Madison Avenue Partners LP's holdings, making the stock its 9th biggest position. Madison Avenue Partners LP owned 2.66% of Indivior worth $45,661,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors also recently added to or reduced their stakes in INDV. Jane Street Group LLC acquired a new position in Indivior during the third quarter worth $180,000. Hennion & Walsh Asset Management Inc. acquired a new stake in Indivior during the 4th quarter valued at $1,192,000. China Universal Asset Management Co. Ltd. purchased a new position in shares of Indivior during the 4th quarter valued at approximately $359,000. Mirae Asset Global Investments Co. Ltd. acquired a new stake in Indivior during the fourth quarter valued at approximately $56,000. Finally, VELA Investment Management LLC boosted its position in Indivior by 45.5% during the 4th quarter. VELA Investment Management LLC now owns 179,659 shares of the company's stock valued at $2,264,000 after purchasing an additional 56,224 shares during the period. Institutional investors and hedge funds own 60.33% of the company's stock.

Indivior Stock Performance

Shares of NASDAQ INDV traded up $0.15 during midday trading on Monday, reaching $11.49. The company's stock had a trading volume of 225,041 shares, compared to its average volume of 1,007,793. The company has a market cap of $1.58 billion, a P/E ratio of -32.71 and a beta of 0.98. Indivior PLC has a fifty-two week low of $7.33 and a fifty-two week high of $18.59. The business's 50 day moving average price is $10.11 and its two-hundred day moving average price is $10.64.

Indivior (NASDAQ:INDV - Get Free Report) last issued its quarterly earnings data on Thursday, April 24th. The company reported $0.41 earnings per share for the quarter, topping the consensus estimate of $0.22 by $0.19. Indivior had a negative net margin of 3.96% and a negative return on equity of 241.73%. The company had revenue of $266.00 million for the quarter, compared to analysts' expectations of $240.13 million. Sell-side analysts forecast that Indivior PLC will post 1.22 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several equities analysts have recently issued reports on the stock. Rodman & Renshaw initiated coverage on shares of Indivior in a research note on Tuesday, January 28th. They issued a "buy" rating and a $16.00 price objective on the stock. RODMAN&RENSHAW raised Indivior to a "strong-buy" rating in a research report on Tuesday, January 28th. Finally, Piper Sandler reduced their target price on shares of Indivior from $16.00 to $13.00 and set an "overweight" rating on the stock in a research note on Thursday, March 6th.

Indivior Profile

Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose.